KARIN HITOMI ISHIKAWA

Dr. KARIN HITOMI ISHIKAWA

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2016 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
VMVictor Haruo Matsubara
Victor Haruo Matsubara
HBH. M. H. N. Bandara
H. M. H. N. Bandara
KIKARIN HITOMI ISHIKAWA
KARIN HITOMI ISHIKAWA
MMMarcia Pinto Alves Mayer
Marcia Pinto Alves Mayer
LSLakshman Perera Samaranayake
Lakshman Perera Samaranayake
The frequent recolonization of treated sites by periodontopathogens and the emergence of antibiotic resistance have led to a call for new therapeutic approaches for managing periodontal diseases. As probiotics are considered a new tool for combating infectious diseases, we systematically reviewed the evidences for their effectiveness in the management of periodontitis. An electronic search was performed in the MEDLINE, SCOPUS and Cochrane Library databases up to March 2016 using the terms 'periodontitis', 'chronic periodontitis', 'probiotic(s)', 'prebiotic(s)', 'symbiotic(s)', 'Bifidobacterium and 'Lactobacillus'. Only randomized controlled trials (RCTs) were included in the present study. Analysis of 12 RCTs revealed that in general, oral administration of probiotics improved the recognized clinical signs of chronic and aggressive periodontitis such as probing pocket depth, bleeding on probing, and attachment loss, with a concomitant reduction in the levels of major periodontal pathogens. Continuous probiotic administration, laced mainly with Lactobacillus species, was necessary to maintain these benefits. Expert commentary: Oral administration of probiotics is a safe and effective adjunct to conventional mechanical treatment (scaling) in the management of periodontitis, specially the chronic disease entity. Their adjunctive use is likely to improve disease indices and reduce the need for antibiotics.

20 August 2014 in Journal of Prosthodontics
Verified
Journal Article
Closed access
PDF file
KIKARIN HITOMI ISHIKAWA
KARIN HITOMI ISHIKAWA
MMMarcia Pinto Alves Mayer
Marcia Pinto Alves Mayer
TMTatiana Y. Miyazima
Tatiana Y. Miyazima
VMVictor H. Matsubara
Victor H. Matsubara
ESEriques G. Silva
Eriques G. Silva
ANAtlas E. M. Nakamae
Atlas E. M. Nakamae

4 October 2018 in Journal of Periodontal Research
Verified
Journal Article
Closed access
PDF file
EAEmmanuel Albuquerque‐Souza
Emmanuel Albuquerque‐Souza
DBDanilo Balzarini
Danilo Balzarini
EAEllen S. Ando‐Suguimoto
Ellen S. Ando‐Suguimoto
KIKARIN HITOMI ISHIKAWA
KARIN HITOMI ISHIKAWA
MSMaria R. L. Simionato
Maria R. L. Simionato
MMMarcia Pinto Alves Mayer
Marcia Pinto Alves Mayer

29 December 2020 in Molecular Oral Microbiology
Verified
Journal Article
Closed access
PDF file
KIKARIN HITOMI ISHIKAWA
KARIN HITOMI ISHIKAWA
MBManuela Rocha Bueno
Manuela Rocha Bueno
DKDione Kawamoto
Dione Kawamoto
MSMaria Regina Lorenzetti Simionato
Maria Regina Lorenzetti Simionato
MMMarcia Pinto Alves Mayer
Marcia Pinto Alves Mayer

1 January 2020 in Journal of Oral Microbiology
Verified
Journal Article
Open access
KIKARIN HITOMI ISHIKAWA
KARIN HITOMI ISHIKAWA
DMDaniela Mita
Daniela Mita
DKDione Kawamoto
Dione Kawamoto
JNJacques Robert Nicoli
Jacques Robert Nicoli
EAEmmanuel Albuquerque-Souza
Emmanuel Albuquerque-Souza
MMMarcia Pinto Alves Mayer
Marcia Pinto Alves Mayer
The potential of probiotics on the prevention and control of periodontitis and other chronic inflammatory conditions has been suggested. Lactobacillus and Bifidobacterium species influence P. gingi...

29 November 2017 in Frontiers in Microbiology
Verified
Journal Article
Open access
VMVictor H. Matsubara
Victor H. Matsubara
KIKARIN HITOMI ISHIKAWA
KARIN HITOMI ISHIKAWA
EAEllen S. Ando-Suguimoto
Ellen S. Ando-Suguimoto
BBBruno Bueno-Silva
Bruno Bueno-Silva
ANAtlas E. M. Nakamae
Atlas E. M. Nakamae
MMMarcia Pinto Alves Mayer
Marcia Pinto Alves Mayer
Probiotics are live microorganisms that confer benefits to the host health. The infection rate of potentially pathogenic organisms such as Candida albicans, the most common agent associated with mucosal candidiasis, can be reduced by probiotics. However, the mechanisms by which the probiotics interfere with the immune system are largely unknown. We evaluated the effect of probiotic bacteria on C. albicans challenged human macrophages. Macrophages were pretreated with lactobacilli alone (Lactobacillus rhamnosus LR32, Lactobacillus casei L324m, or Lactobacillus acidophilus NCFM) or associated with Escherichia coli lipopolysaccharide (LPS), followed by the challenge with C. albicans or LPS in a co-culture assay. The expression of pattern-recognition receptors genes (CLE7A, TLR2, and TLR4) was determined by RT-qPCR, and dectin-1 reduced levels were confirmed by flow cytometry. The cytokine profile was determined by ELISA using the macrophage cell supernatant. Overall probiotic lactobacilli down-regulated the transcription of CLEC7A (p < 0.05), resulting in the decreased expression of dectin-1 on probiotic pretreated macrophages. The tested Lactobacillus species down-regulated TLR4, and increased TLR2 mRNA levels in macrophages challenged with C. albicans. The cytokines profile of macrophages challenged with C. albicans or LPS were altered by the probiotics, which generally led to increased levels of IL-10 and IL-1β, and reduction of IL-12 production by macrophages (p < 0.05). Our data suggest that probiotic lactobacilli impair the recognition of PAMPs by macrophages, and alter the production of pro/anti-inflammatory cytokines, thus modulating inflammation.